Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,479 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel quality indicators for metastatic colorectal cancer management identify significant variations in these measures across treatment centers in Australia.
Turner NH, Wong HL, Field K, Wong R, Shapiro J, Yip D, Nott L, Tie J, Kosmider S, Tran B, Desai J, McKendrick J, Zimet A, Richardson G, Iddawela M, Gibbs P. Turner NH, et al. Among authors: tran b. Asia Pac J Clin Oncol. 2015 Sep;11(3):262-71. doi: 10.1111/ajco.12355. Epub 2015 Apr 14. Asia Pac J Clin Oncol. 2015. PMID: 25871458
Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
Wong HL, Lee B, Field K, Lomax A, Tacey M, Shapiro J, McKendrick J, Zimet A, Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Wong HL, et al. Among authors: tran b. Clin Colorectal Cancer. 2016 Jun;15(2):e9-e15. doi: 10.1016/j.clcc.2016.02.007. Epub 2016 Feb 13. Clin Colorectal Cancer. 2016. PMID: 26968236
The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study.
Lee B, Wong HL, Tacey M, Tie J, Wong R, Lee M, Nott L, Shapiro J, Jennens R, Turner N, Tran B, Ananda S, Yip D, Richardson G, Parente P, Lim L, Stefanou G, Burge M, Iddawela M, Power J, Gibbs P. Lee B, et al. Among authors: tran b. Asia Pac J Clin Oncol. 2017 Aug;13(4):314-321. doi: 10.1111/ajco.12639. Epub 2016 Nov 25. Asia Pac J Clin Oncol. 2017. PMID: 27885818
Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Hamid AA, Willson K, Vincent AD, Tamjid B, Lee M, Bergin A, Gan C, Campbell A, Stewart J, Pezaro C, Tran B, Weickhardt AJ. Hamid AA, et al. Among authors: tran b. Asia Pac J Clin Oncol. 2018 Oct;14(5):e399-e404. doi: 10.1111/ajco.12840. Epub 2018 Jan 10. Asia Pac J Clin Oncol. 2018. PMID: 29318740
Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease.
Schmidt A, Anton A, Shapiro J, Wong S, Azad A, Kwan E, Spain L, Muthusamy A, Torres J, Parente P, Parnis F, Goh J, Joshua AM, Pook D, Gibbs P, Tran B, Weickhardt A. Schmidt A, et al. Among authors: tran b. Asia Pac J Clin Oncol. 2021 Feb;17(1):36-42. doi: 10.1111/ajco.13447. Epub 2020 Sep 24. Asia Pac J Clin Oncol. 2021. PMID: 32970925
1,479 results